Yedida Y Bogachkov PhD,  —

The first patient has been dosed in the resumed Phase 2a clinical trial of montelukast for mild to moderate Alzheimer’s disease. IntelGenx, the company running the study known as BUENA (NCT03402503), suspended the trial in late 2020 due to increased concern regarding the COVID-19 pandemic. “Resumption of…

The National Institutes of Health (NIH) awarded $2 million to investigators studying how chronic physiological stress may cause vascular changes and exacerbate the cognitive decline seen in Alzheimer’s disease. Paul Chantler, PhD, an associate professor at West Virginia University School of Medicine, and his team are also using animal…

Longeveron is initiating a Phase 2a clinical trial for its Lomecel-B treatment — an investigational, bone marrow-derived, medicinal signaling cell (MSC) — in patients with mild Alzheimer’s disease. The first patient has already given consent to participate in the trial, and further patient screening has begun. “We are…

An international clinical trial for gantenerumab aimed at preventing inherited, early-onset Alzheimer’s disease is being launched at the Washington University School of Medicine in St. Louis. The trial, called the Primary Prevention Trial, is enrolling people with a family history of early-onset Alzheimer’s and its associated genetic…

Acadia Pharmaceuticals intends to again request that oral Nuplazid (pimavanserin) be approved to treat hallucinations and delusions, but this time only when associated with the dementia-related psychosis of Alzheimer’s disease. Its planned request to the U.S. Food and Drug Administration (FDA), in the form of a resubmitted supplemental new…

I-Mab Biopharma announced that the first patient has been dosed in the U.S.-based Phase 1 trial of its intranasal immunotherapy agent Protollin — an investigational medication being developed to treat those with early Alzheimer’s disease. The U.S. Food and Drug Administration approved the company’s request for this safety and…

The Tau Next Generation (Tau NexGen) clinical trial will now be evaluating an anti-amyloid antibody in addition to an anti-tau antibody as a potential treatment for early onset Alzheimer’s disease, according to a press release. Lecanemab, an investigational treatment being co-developed by Eisai and Biogen, has been selected as…

AC Immune has announced it will extend its partnership with researchers at the University of Pennsylvania to further study the mechanisms underlying disease-causing changes in  the transactive response DNA binding protein 43 kDa (TDP-43). Specifically, company researchers and those with the university’s Center for Neurodegenerative Disease Research at the Perelman School of Medicine…

The MassAITC project was recently launched to focus on using artificial intelligence (AI) to improve in-home care for older adults and others with Alzheimer’s disease, with the help of a five-year, $20-million grant from the National Institute on Aging, a part of the National Institutes of Health. MassAITC,…

The first patient has been recruited, in Finland, for Alzinova AB’s Phase 1b clinical trial testing its ALZ-101 vaccine for Alzheimer’s disease, the company announced. Alzinova AB, a Swedish biopharma company, is working to develop treatments for Alzheimer’s that specifically target amyloid-beta oligomers — chains of several single…